Looks like it’s OK for our drug price gouging buddy Martin Shkreli to head to Washington this and testify before that drug pricing congressional committee, Stat News reports.
The U.S. Department of Justice yesterday wrote a letter that sanctions Shkreli’s travel to D.C. for a Feb. 4 hearing – despite Shkreli saying he couldn’t leave New York thanks to the terms of his bail.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Shkreli, after all, is out on a $5 million bail for unrelated securities fraud charges for his “Ponzi-like” scheming at previous companies. The former Turing Pharmaceuticals CEO is entwined in a complex web of legal issues – with an FTC investigation underway for antitrust violations, a congressional subpoena for drug price gouging and, of course, securities fraud.
The hearing was initially scheduled for Jan. 26, but postponed to February due to the recent blizzard.